We have an ongoing Phase 1 clinical study for product candidate MRG-106, a synthetic microRNA antagonist (LNA antimiR®) of microRNA-155, and recently completed a Phase 1 clinical study for product candidate MRG-201, a synthetic microRNA mimic (promiR) to microRNA-29b.
MRG-106 Anti-cancer Product Candidate
The Phase 1 study, MRG106-11-101, is designed to evaluate the safety and tolerability of the investigational drug, MRG-106. MRG-106 is a synthetic microRNA antagonist (LNA antimiR®) of microRNA-155. In hematological malignancy microRNA-155 has key roles in the differentiation, function and proliferation of blood and lymph cells. In laboratory tests inhibition (antagonism) of microRNA-155 in lymphoma cells restores normal function and reduces aberrant cell proliferation. The Phase 1 trial of MRG-106 is being conducted in patients suffering from cutaneous T-cell lymphoma (CTCL) of the mycosis fungoides (MF) sub-type and in addition to assessments of safety, tolerability and pharmacokinetics, the trial will also assess the molecular signature of MRG-106 in the lesions of MF patients.
MRG-201 Anti-fibrosis Product Candidate
The Phase 1 study, MRG201-30-001, was designed to evaluate the safety and tolerability of the investigational drug, MRG-201. MRG-201 is designed to mimic the activity of microRNA miR-29b and decrease the expression of collagen and other proteins that are involved in fibrous scar formation. MRG-201 was being tested in healthy volunteers by intradermal injection of the drug into intact skin or adjacent to a short skin incision. Skin biopsies were also collected to study how cells in the skin respond when exposed to MRG-201.